Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

April 30, 2016

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

DRUG

Placebo

DRUG

Alirocumab

Trial Locations (13)

Aurora

Hartford

Kansas City

Scarborough

Rochester

Portland

Philadelphia

Dresden

Berlin

Göttingen

Muenchen (2 Locations)

Passau

Rostock